皮康王品牌怎么样 申请店铺

我要投票 皮康王在保健药品行业中的票数:730 更新时间:2025-12-31
皮康王是哪个国家的品牌?「皮康王」是 拜耳医药保健有限公司 旗下著名品牌。该品牌发源于云南省昆明市,在1993年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力皮康王品牌出海!将品牌入驻外推网,定制皮康王品牌推广信息,可以显著提高皮康王产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

皮康王怎么样


“皮康王”最初由上海部队院校研制成功,具有神秘的军队血统。曾因帮助老山前线部队解决了因湿热环境引发的脚癣、体癣、股癣及皮肤瘙痒等问题,被誉为“皮疾克星”。后在国家政策放开的情况下由滇虹药业最早获得“军转民”的生产资格,于1993年隆重上市。

滇虹药业集团前身为中美合资昆明滇虹药业有限公司,系由滇虹天然药物厂与美国大东企业于1997年合资设立,承继1993年注册成立的滇虹天然药物厂的全部业务,设立至今始终由中方控股。2012年,昆明滇虹药业有限公司改制变更为滇虹药业集团股份有限公司。2014年3月,拜耳集团完成对滇虹药业集团公司所有股份的收购。滇虹药业集团公司正式成为拜耳集团子公司。

滇虹药业集团是一家研发导向型、集研发、生产和营销为一体的现代化制药企业集团。滇虹药业现有员工3000余名,营销网络覆盖全国乃至东南亚国家及非洲地区。作为云药产业发展的中坚力量,滇虹药业勇于创新、积极开拓,已成长为中国医药行业的知名企业。

通过持续的品牌建设,滇虹药业主品牌“康王”以其广泛的美誉度和影响力,经国家工商行政管理总局及最高人民法院联合认定为“中国驰名商标”,同时上榜“亚洲最具价值500强品牌”。集团旗下产品以质量可靠、疗效确切赢得众多患者青睐。其中包括被誉为“去屑专家”的“康王发用洗剂”以及被誉为“皮疾克星”的“皮康王”、妇科知名产品“丹莪妇康煎膏”等一批享誉国内外的品牌产品。

伴随企业社会知名度和美誉度的不断提升,公司正式确立了植根于品牌的“以消费者大健康产业为主体,以拓展医药及国际市场为两翼”的“一体两翼”消费者大健康产业发展战略。在这一战略指引下,滇虹药业积极推动中国负责任的自我保健及自我药疗事业进程,推动设立国际自我保健日。同时展开产业整合,打造中药标准化平台,集中优势资源将民族品牌做强做大。

滇虹药业被国家五部委联合认定为“国家级企业技术中心”,被云南省人民政府列为“省重点制药企业”,被中华全国工商联和国家税务总局评为“诚信纳税”企业,被全国总工会和中华全国工商联评为“双爱双评”先进企业。多次荣获国家有关部委、省市区各级政府表彰奖励,多次接待国家和国外领导人、省市领导的参观访问。

依托高质量的产品优势和良好的企业文化积淀,滇虹药业气势如虹,开疆拓土,在大健康产业领域以良好的发展态势傲视同侪。秉持“以人为本、艰苦奋斗、科技兴药”的企业理念,怀着“关注健康,造福人类”的企业追求,滇虹愿与社会各界人士携手,共襄医药产业美好未来。


"King Picon" was originally developed by Shanghai military academy, which has a mysterious military pedigree. He once helped Laoshan front-line army to solve the problems of tinea cruris, tinea corporis, tinea cruris and pruritus caused by humid and hot environment, which was known as "skin disease killer". After the opening of the national policy, Dian Hong pharmaceutical industry was the first to obtain the qualification of "military to civilian" production, which was solemnly listed in 1993. Yunnan Hong Pharmaceutical Group, formerly known as Sino US joint venture Kunming Yunnan Hong Pharmaceutical Co., Ltd., is a joint venture established by Yunnan Hong Natural Pharmaceutical Co., Ltd. and Dadong enterprise of the United States in 1997. It inherits all businesses of Yunnan Hong Natural Pharmaceutical Co., Ltd. registered in 1993 and has been controlled by China ever since its establishment. In 2012, the restructuring of Kunming Dianhong Pharmaceutical Co., Ltd. was changed to Dianhong Pharmaceutical Group Co., Ltd. In March 2014, Bayer Group completed the acquisition of all shares of Dianhong Pharmaceutical Group. Dianhong pharmaceutical group company has officially become a subsidiary of Bayer Group. Dianhong Pharmaceutical Group is a R & D-oriented, research and development, production and marketing as one of the modern pharmaceutical enterprise groups. Dianhong pharmaceutical has more than 3000 employees, and its marketing network covers the whole country, even Southeast Asian countries and Africa. As the backbone of the development of Yunnan pharmaceutical industry, Dianhong pharmaceutical industry has the courage to innovate and actively explore, and has grown into a well-known enterprise in China's pharmaceutical industry. Through continuous brand building, the owner brand of Dianhong Pharmaceutical Co., Ltd. "Kangwang", with its extensive reputation and influence, was jointly recognized as "China's famous trademark" by the State Administration for Industry and Commerce and the Supreme People's court, and listed as "the most valuable 500 brands in Asia". The group's products have won the favor of many patients with reliable quality and exact curative effect. Among them, "Kangwang hair lotion" which is known as "Dandruff removal expert" and "picongwang" which is known as "pixixing" and "Dane Fukang Decoction", which is a famous gynecological product, are well-known brand products at home and abroad. With the continuous improvement of corporate social popularity and reputation, the company has officially established the "one body and two wings" development strategy of consumer health industry, which is rooted in the brand and takes the consumer health industry as the main body and the expansion of medicine and international market as the two wings. Under the guidance of this strategy, Dianhong pharmaceutical actively promotes China's responsible self-care and self medication career, and promotes the establishment of the international self care day. At the same time, we will carry out industrial integration, build a platform for standardization of traditional Chinese medicine, and focus on advantageous resources to strengthen and expand national brands. Dianhong pharmaceutical industry is jointly recognized as "national enterprise technology center" by five ministries and commissions of the state, as "provincial key pharmaceutical enterprise" by Yunnan Provincial People's government, as "honest tax payment" enterprise by all China Federation of industry and Commerce and State Administration of Taxation, and as "double love and double evaluation" advanced enterprise by all China Federation of trade unions and all China Federation of industry and commerce. It has won many awards from relevant national ministries and commissions, provincial and municipal governments at all levels, and received many visits from national and foreign leaders and provincial and municipal leaders. Relying on the advantages of high-quality products and good corporate culture accumulation, Dianhong pharmaceutical industry is in a great momentum, expanding its territory and dominating its peers in the field of big health industry with a good development momentum. Adhering to the enterprise philosophy of "people-oriented, hard work, science and technology to promote medicine" and the enterprise pursuit of "focusing on health and benefiting mankind", Dianhong is willing to work with people from all walks of life to share the bright future of medicine industry.

本文链接: https://brand.waitui.com/3539f7c8f.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

国家统计局:12月官方制造业PMI 50.1,比上月上升0.9个百分点

36氪获悉,国家统计局数据显示,12月份,制造业采购经理指数(PMI)为50.1%,比上月上升0.9个百分点,升至扩张区间。从企业规模看,大型企业PMI为50.8%,比上月上升1.5个百分点,高于临界点;中型企业PMI为49.8%,比上月上升0.9个百分点,仍低于临界点;小型企业PMI为48.6%,比上月下降0.5个百分点,低于临界点。从分类指数看,在构成制造业PMI的5个分类指数中,生产指数、新订单指数和供应商配送时间指数均高于临界点,原材料库存指数和从业人员指数均低于临界点。

2小时前

央行开展5288亿元7天期逆回购操作

36氪获悉,央行公开市场开展5288亿元7天期逆回购操作,操作利率1.40%,与前次持平。今日有260亿元逆回购到期。

2小时前

中信证券:银行需把握数字人民币渗透率提升机会

36氪获悉,中信证券研报表示,数字人民币正由替代现金的“央行负债型”1.0,升级为纳入商业银行负债体系的“存款货币型”2.0,其账户可计息、缴准,实质成为一般性存款。这一制度性调整有助于夯实银行负债稳定性,并强化准备金与利率框架下的货币政策传导效率,同时显著提升商业银行推广数字人民币的内生激励。从行业影响看,数字人民币有望成为对公与零售联动的重要工具,并在支付环节对第三方平台形成一定替代。预计后续银行数字人民币业务发展重心将由资格转向能力,银行需加快从账户运营走向场景化专业化服务,把握数字人民币渗透率提升机会。

2小时前

12月RatingDog制造业PMI 50.1,前值49.9

36氪获悉,12月RatingDog制造业PMI 50.1,前值49.9。

2小时前

“唯精医疗”完成亿元级B+轮融资

36氪获悉,“唯精医疗”今日宣布,已完成亿元级B+轮融资。本轮融资由国泰海通证券旗下国泰君安创新投资有限公司的独家投资,同时战略股东康基医疗继续追加投资,歌路资本担任本次交易的独家财务顾问。此次募集资金将主要用于加速产品商业化进程,并推动新一代产品的研发与临床注册。

2小时前

本页详细列出关于皮康王的品牌信息,含品牌所属公司介绍,皮康王所处行业的品牌地位及优势。
咨询